Cannabidiol (CBD) Products: Use Patterns and Perceptions Within a Sample of Anxious Users

References

• Abrams, D. I. (2018). The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine, 49, 7–11. https://doi.org/10.1016/J.EJIM.2018.01.003
   PubMed Web of Science ®Google Scholar
• Agriculture Improvement Act of 2018 Pub. L. 115–334, 132 Stat. https://www.congress.gov/115/plaws/publ334/PLAW-115publ334.pdf
   Google Scholar
• Antony, M. M., Bieling, P. J., Cox, B. J., Enns, M. W., & Swinson, R. P. (1998). Psychometric properties of the 42-Item and 21-Item versions of the depression anxiety stress scales in clinical groups and a community sample. In Psychological Assessment, 10 (2), 176–181. (https://doi.org/10.1037/1040-3590.10.2.176
   Web of Science ®Google Scholar
• Arnold, J. C., McCartney, D., Suraev, A., & McGregor, I. S. (2023). The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clinical and Translational Science, 16(1), 10–30. https://doi.org/10.1111/cts.13425
   PubMed Web of Science ®Google Scholar
• Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., De Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-nave social phobia patients. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 36(6), 1219–1226. https://doi.org/10.1038/npp.2011.6
   PubMed Web of Science ®Google Scholar
• Berger, M., Li, E., Rice, S., Davey, C. G., Ratheesh, A., Adams, S., Jackson, H., Hetrick, S., Parker, A., Spelman, T., Kevin, R., McGregor, I. S., McGorry, P., & Amminger, G. P. (2022). Cannabidiol for treatment-resistant anxiety disorders in young people: An open-label trial. The Journal of Clinical Psychiatry, 83(5) https://doi.org/10.4088/JCP.21m14130
   PubMed Web of Science ®Google Scholar
• Bergeria, C. L., Strickland, J. C., Spindle, T. R., Kalaba, M., Satyavolu, P. U., Feldner, M., Vandrey, R., Bonn-Miller, M., Peters, E. N., & Weerts, E. (2022). A crowdsourcing survey study on the subjective effects of Delta-8-tetrahydrocannabinol relative to Delta-9-tetrahydrocannabinol and cannabidiol. Experimental and Clinical Psychopharmacology, 31(2), 312–317. https://doi.org/10.1037/PHA0000565
   PubMed Web of Science ®Google Scholar
• Bitencourt, R. M., & Takahashi, R. N. (2018). Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: From bench research to confirmation in human trials. Frontiers in Neuroscience, 12, 502. https://doi.org/10.3389/fnins.2018.00502
   PubMed Web of Science ®Google Scholar
• Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 12(4), 825–836. https://doi.org/10.1007/s13311-015-0387-1
   PubMed Web of Science ®Google Scholar
• Bolsoni, L. M., Crippa, J. A. S., Hallak, J. E. C., Guimarães, F. S., & Zuardi, A. W. (2022). Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology, 239(5), 1499–1507. https://doi.org/10.1007/s00213-021-06043-y
   PubMed Web of Science ®Google Scholar
• Bonn-Miller, M. O., Babson, K. A., & Vandrey, R. (2014). Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD. Drug and Alcohol Dependence, 136(1), 162–165. https://doi.org/10.1016/j.drugalcdep.2013.12.008
   PubMedGoogle Scholar
• Brenan, M. (2019). 14% of Americans Say They Use CBD Products. Gallup. https://news.gallup.com/poll/263147/americans-say-cbd-products.aspx
   Google Scholar
• Cascio, M. A., Lee, E., Vaudrin, N., & Freedman, D. A. (2019). A team-based approach to open coding: Considerations for creating intercoder consensus. Field Methods, 31(2), 116–130. https://doi.org/10.1177/1525822X19838237
   Web of Science ®Google Scholar
• Chesney, E., Oliver, D., Green, A., Sovi, S., Wilson, J., Englund, A., Freeman, T. P., & McGuire, P. (2020). Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 45(11), 1799–1806. https://doi.org/10.1038/s41386-020-0667-2
   PubMed Web of Science ®Google Scholar
• Corroon, J., & Phillips, J. A. (2018). A cross-sectional study of cannabidiol users. Cannabis and Cannabinoid Research, 3(1), 152–161. https://doi.org/10.1089/CAN.2018.0006/ASSET/IMAGES/LARGE/FIGURE3.JPEG
   PubMedGoogle Scholar
• Crippa, J. A. S., Nogueira Derenusson, G., Borduqui Ferrari, T., Wichert-Ana, L., Duran, F. L. S., Martin-Santos, R., Vinícius Simões, M., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., & Hallak, J. E. C. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology, 25(1), 121–130. https://doi.org/10.1177/0269881110379283
   PubMed Web of Science ®Google Scholar
• Crippa, J. A. S., Zuardi, A. W., Guimarães, F. S., Campos, A. C., de Lima Osório, F., Loureiro, S. R., Dos Santos, R. G., Souza, J. D. S., Ushirohira, J. M., Pacheco, J. C., Ferreira, R. R., Mancini Costa, K. C., Scomparin, D. S., Scarante, F. F., Pires-Dos-Santos, I., Mechoulam, R., Kapczinski, F., Fonseca, B. A. L., Esposito, D. L. A., … Hallak, J. E. C, (2021). Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: A randomized clinical trial. JAMA Network Open, 4(8), e2120603. https://doi.org/10.1001/jamanetworkopen.2021.20603
   PubMed Web of Science ®Google Scholar
• Dahlgren, M. K., Sagar, K. A., Lambros, A. M., Smith, R. T., & Gruber, S. A. (2021). Urinary tetrahydrocannabinol after 4 weeks of a full-spectrum, high-cannabidiol treatment in an open-label clinical trial. JAMA Psychiatry, 78(3), 335–337. https://doi.org/10.1001/JAMAPSYCHIATRY.2020.3567
   PubMed Web of Science ®Google Scholar
• Dorbian, I. (2019). CBD Market Could Reach $20 Billion By 2024, Says New Study. Forbes. https://www.forbes.com/sites/irisdorbian/2019/05/20/cbd-market-could-reach-20-billion-by-2024-says-new-study/?sh=30f2b55049d0
   Google Scholar
• Drug Enforcement Agency. (2018). Drug Scheduling. https://www.dea.gov/drug-information/drug-scheduling
   Google Scholar
• Ferretti, M. L., Vandrey, R., Irons, J. G., Jackson, H., Loflin, M. J., Hyke, T., & Bonn-Miller, M. O. (2023). Likelihood of positive urine screens of THC-COOH after daily use of full-spectrum hemp extracts varies as a function of screening criterion used. Therapeutic Drug Monitoring, 45(1), 126–127. https://doi.org/10.1097/FTD.0000000000001032
   PubMed Web of Science ®Google Scholar
• Grayson, L., Vines, B., Nichol, K., & Szaflarski, J. P. (2018). An interaction between warfarin and cannabidiol, a case report. Epilepsy & behavior case reports, 9, 10–11.
   PubMed Web of Science ®Google Scholar
• Hammond, D., & Goodman, S. (2022). Knowledge of tetrahydrocannabinol and cannabidiol Levels among cannabis consumers in the United States and Canada. Cannabis and Cannabinoid Research, 7(3), 345–354. https://doi.org/10.1089/CAN.2020.0092/SUPPL_FILE/SUPP_TABLES1-S9.DOCX
   PubMedGoogle Scholar
• Harrison, N. J., & Simpson, H. (2021). Nabilone (Cesamet). In Cannabinoids and Pain (pp. 109–112). Springer International Publishing.
   Google Scholar
• Hawes, E. M., Lee, C. R., Brackney, D. E., Ensley, T. G., Kidd, J., & Page, C. (2020). Cannabidiol products: Review of the regulatory and clinical considerations. The Journal for Nurse Practitioners, 16(10), 747–755. https://doi.org/10.1016/j.nurpra.2020.07.022
   Google Scholar
• Hindocha, C., Freeman, T. P., Grabski, M., Stroud, J. B., Crudgington, H., Davies, A. C., Das, R. K., Lawn, W., Morgan, C. J. A., & Curran, H. V. (2018). Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction, 113(9), 1696–1705. https://doi.org/10.1111/add.14243
   PubMed Web of Science ®Google Scholar
• Hundal, H., Lister, R., Evans, N., Antley, A., Englund, A., Murray, R. M., Freeman, D., & Morrison, P. D. (2018). The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. Journal of Psychopharmacology, 32(3), 276–282. https://doi.org/10.1177/0269881117737400/ASSET/IMAGES/LARGE/10.1177_0269881117737400-FIG2.JPEG
   PubMed Web of Science ®Google Scholar
• Hurd, Y. L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E. (2019). Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. The American Journal of Psychiatry, 176(11), 911–922. https://doi.org/10.1176/APPI.AJP.2019.18101191/ASSET/IMAGES/LARGE/APPI.AJP.2019.18101191F4.JPEG
   PubMed Web of Science ®Google Scholar
• Jiang, H., Li, H., Cao, Y., Zhang, R., Zhou, L., Zhou, Y., Zeng, X., Wu, J., Wu, D., Wu, D., Guo, X., Li, X., Wu, H., & Li, P. (2021). Effects of cannabinoid (CBD) on blood brain barrier permeability after brain injury in rats. Brain Research, 1768, 147586. https://doi.org/10.1016/J.BRAINRES.2021.147586
   PubMed Web of Science ®Google Scholar
• Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management, 39(2), 167–179. https://doi.org/10.1016/J.JPAINSYMMAN.2009.06.008
   PubMed Web of Science ®Google Scholar
• Kwee, C. M., Baas, J. M., van der Flier, F. E., Groenink, L., Duits, P., Eikelenboom, M., van der Veen, D. C., Moerbeek, M., Batelaan, N. M., van Balkom, A. J., & Cath, D. C. (2022). Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 59, 58–67. https://doi.org/10.1016/j.euroneuro.2022.04.003
   PubMed Web of Science ®Google Scholar
• LaFrance, E. M., Glodosky, N. C., Bonn-Miller, M., & Cuttler, C. (2020). Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. Journal of Affective Disorders, 274, 298–304. https://doi.org/10.1016/J.JAD.2020.05.132
   PubMed Web of Science ®Google Scholar
• Leas, E. C., Hendrickson, E. M., Nobles, A. L., Todd, R., Smith, D. M., Dredze, M., & Ayers, J. W. (2020). Self-reported Cannabidiol (CBD) Use for Conditions With Proven Therapies. JAMA Network Open, 3(10), e2020977–e2020977. https://doi.org/10.1001/JAMANETWORKOPEN.2020.20977
   Web of Science ®Google Scholar
• Leino, A. D., Emoto, C., Fukuda, T., Privitera, M., Vinks, A. A., & Alloway, R. R. (2019). Evidence of a clinically significant drug‐drug interaction between cannabidiol and tacrolimus. American Journal of Transplantation, 19(10), 2944–2948.
   PubMed Web of Science ®Google Scholar
• Li, J., Carvajal, R., Bruner, L., & Kaminski, N. E. (2021). The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association, 157, 112600. https://doi.org/10.1016/J.FCT.2021.112600
   PubMed Web of Science ®Google Scholar
• Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Revista Brasileira de Psiquiatria, 41(1), 9–14. https://doi.org/10.1590/1516-4446-2017-0015
   PubMedGoogle Scholar
• Loflin, M. J., Babson, K. A., & Bonn-Miller, M. O. (2017). Cannabinoids as therapeutic for PTSD. Current Opinion in Psychology, 14, 78–83. https://doi.org/10.1016/J.COPSYC.2016.12.001
   PubMed Web of Science ®Google Scholar
• Masataka, N. (2019). Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Frontiers in Psychology, 10, 2466. https://doi.org/10.3389/fpsyg.2019.02466
   PubMedGoogle Scholar
• Moltke, J., & Hindocha, C. (2021). Reasons for cannabidiol use: A cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. Journal of Cannabis Research, 3(1), 5. https://doi.org/10.1186/s42238-021-00061-5
   PubMedGoogle Scholar
• Nanthakumar, S., Bucks, R. S., Skinner, T. C., Starkstein, S., Hillman, D., James, A., & Hunter, M. (2016). Assessment of the Depression, Anxiety, and Stress Scale (DASS-21) in Untreated Obstructive Sleep Apnea (OSA).
   Google Scholar
• Passie, T., Emrich, H. M., Karst, M., Brandt, S. D., & Halpern, J. H. (2012). Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence. Drug Testing and Analysis, 4(7-8), 649–659. https://doi.org/10.1002/dta.1377
   PubMed Web of Science ®Google Scholar
• Rock, E. M., Sullivan, M. T., Collins, S. A., Goodman, H., Limebeer, C. L., Mechoulam, R., & Parker, L. A. (2020). Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. Psychopharmacology, 237(9), 2621–2631. https://doi.org/10.1007/s00213-020-05559-z/Published
   PubMed Web of Science ®Google Scholar
• Russo, E. B., Cuttler, C., Cooper, Z. D., Stueber, A., Whiteley, V. L., & Sexton, M. (2022). Survey of patients employing cannabigerol-predominant cannabis preparations: Perceived medical effects, adverse events, and withdrawal symptoms. Cannabis and Cannabinoid Research, 7(5), 706–716. https://doi.org/10.1089/can.2021.0058
   PubMedGoogle Scholar
• Souza, J. D. R., Pacheco, J. C., Rossi, G. N., de-Paulo, B. O., Zuardi, A. W., Guimarães, F. S., Hallak, J. E. C., Crippa, J. A., & Dos Santos, R. G. (2022). Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, 14(12), 2598. https://doi.org/10.3390/pharmaceutics14122598
   PubMed Web of Science ®Google Scholar
• Spindle, T. R., Cone, E. J., Goffi, E., Weerts, E. M., Mitchell, J. M., Winecker, R. E., Bigelow, G. E., Flegel, R. R., & Vandrey, R. (2020a). Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug and Alcohol Dependence, 211, 107937. https://doi.org/10.1016/j.drugalcdep.2020.107937
   PubMed Web of Science ®Google Scholar
• Spindle, T. R., Cone, E. J., Kuntz, D., Mitchell, J. M., Bigelow, G. E., Flegel, R., & Vandrey, R. (2020b). Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis. Journal of Analytical Toxicology, 44(2), 109–125. https://doi.org/10.1093/JAT/BKZ080
   PubMed Web of Science ®Google Scholar
• Spinella, T. C., Stewart, S. H., Naugler, J., Yakovenko, I., & Barrett, S. P. (2021). Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: A randomized crossover study. Psychopharmacology, 238(7), 1965–1977. https://doi.org/10.1007/s00213-021-05823-w/Published
   PubMed Web of Science ®Google Scholar
• Walukevich-Dienst, K., Morris, P. E., Tucker, R. P., Copeland, A. L., & Buckner, J. D. (2022). Development and initial psychometric properties of the cannabidiol outcome expectancies questionnaire (CBD-OEQ). Psychological Assessment, 34(7), 643–659. https://doi.org/10.1037/pas0001128
   PubMed Web of Science ®Google Scholar
• Wheeler, M., Merten, J. W., Gordon, B. T., & Hamadi, H. (2020). CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults. Substance Use & Misuse, 55(7), 1138–1145. https://doi.org/10.1080/10826084.2020.1729201
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2017). Drugs (psychoactive): Cannabidiol (compound of cannabis). https://www.who.int/news-room/questions-and-answers/item/cannabidiol-(compound-of-cannabis)
   Google Scholar
• Wysota, C. N., Henriksen, L., Romm, K. F., Duan, Z., Wang, Y., Huang, J., & Berg, C. J. (2022). Cannabidiol Knowledge, Perceptions, and Use Among Young Adults in 6 U.S. https://Home.Liebertpub.Com/Can. https://doi.org/10.1089/CAN.2022.0029
   Google Scholar
• Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017). Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Frontiers in Pharmacology, 8(MAY), 259. https://doi.org/10.3389/fphar.2017.00259
   PubMedGoogle Scholar